Company news
Hoth Therapeutics, Inc. news in 2025
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
December 3, 2025
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
December 1, 2025
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
November 20, 2025
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
October 27, 2025
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
October 21, 2025
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
October 8, 2025
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
October 7, 2025
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
September 24, 2025
Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History
September 16, 2025
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities
September 10, 2025
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
September 4, 2025
Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
September 2, 2025
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
July 29, 2025
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
July 22, 2025
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
June 25, 2025
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
June 24, 2025
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
June 23, 2025
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
June 18, 2025
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway
June 18, 2025
Hoth Therapeutics to Attend 2025 BIO International Convention
June 16, 2025
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
June 12, 2025
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
June 11, 2025
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
June 5, 2025
Correction: Hoth Therapeutics, Inc.
May 12, 2025
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
April 17, 2025
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
April 15, 2025
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
April 2, 2025
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours
April 2, 2025
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
March 31, 2025
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
March 26, 2025
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
March 18, 2025
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
March 10, 2025
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
March 5, 2025
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
March 4, 2025
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
February 9, 2025
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
January 23, 2025
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
January 20, 2025
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
January 6, 2025
Decks in 2025
- Investor Presentation (October 2025)
Investor deck · 24 slides · October 2025
- Investor Presentation (June 2025)
Investor deck · 28 slides · June 2025